Clinical trial
Long Term Study of VAH631 in Patients With Essential Hypertension (Extension…
NCT00338936 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00338936 |
|---|---|
| Title | Long Term Study of VAH631 in Patients With Essential Hypertension (Extension From B1303 Study) |
| Official title | A 52-week Extension to the Factorial Study to Evaluate the Efficacy and Safety of VAH631 (Valsartan and Hydrochlorothiazide Combined) and Alone in Essential Hypertensive Patients - Long Term Study of VAH631 in Patients With Essential Hypertension (Extension From B1303 Study) - |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hypertension |
| Intervention type | Drug |
| Interventions | Valsartan + Hydrochlorothiazide |
| Enrollment | 362 |
| Start date | May 1, 2006 |
| Primary completion | Sep 1, 2007 |
| Completion | Sep 1, 2007 |
| First posted | Jun 20, 2006 |
| Last update posted | Nov 8, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: